With the development of growth factors and growth factor modulators as therapeutics for a
range of disorders, it is prudent to consider whether modulating the growth factor profile in a
tissue can influence tumour initiation or progression. As recombinant human TGF-β3
(avotermin) is being developed for the improvement of scarring in the skin it is important to
understand the role, if any, of this cytokine in tumour progression. Elevated levels of TGF-β3
expression detected in late-stage tumours have linked this cytokine with tumourigenesis …